Some studies indicated that CDCA2 act for a very powerful prognostic marker for poor patient survival and malignancy in cancers such as neuroblastoma, lung adenocarcinoma, and oral squamous cell carcinoma tissue[32–34]. This evidence concerns the gene CDCA2 and cancer.